TRANSMITTAL SHEET FOR NOTICE OF INTENDED ACTION

Control	420	Alabama Dep	partment of Public Health				
Rule Number <u>420-4-1 Appendix II</u> Rule Title <u>Routine Prenatal Screening for Sexually Transmitted Disease (STD)</u>							
New	Amend	XXXX RepealAd	lopt by Reference				
Would the absendendanger the pub		osed rule significantly harm or fare or safety?	Yes				
		ip between the state's police public health, safety or welfar	e? <u>Yes</u>				
	Is there another, less restrictive method of regulation available that could adequately protect the public? No						
		e effect of directly or indirectly ds or services involved and, if s					
		nore harmful to the public than the absence of the proposed ru	ıle? <u>n/a</u>				
		process designed solely for the their primary effect, the protec					
Does the propose	d rule have an	economic impact?	<u>No</u>				
If the proposed rule has an economic impact, the proposed rule is required to be accompanied by a fiscal note prepared in accordance with subsection (f) of §41-22-23, Code of Alabama, 1975.							
Certification of A	authorized Off	icial					
I certify that the attached proposed rule has been in full compliance with the requirements of Chapter 22, Title 41, Code of Alabama, 1975, and that it conforms to all applicable filing requirements of the Administrative Procedure Division of the Legislative Reference Service.							
Signature of Cert	ifying Officer	Jahim The	- Date 6/16/2014				

FORM APA2 11/96

STATE BOARD OF HEALTH NOTICE OF INTENDED ACTION

AGENCY NAME: Alabama Department of Public Health

RULE NUMBER AND TITLE: 420-4-1 Appendix II, Routine Prenatal Screening for Sexually Transmitted Disease (STD)

INTENDED ACTION: Repeal of 420-4-1 Appendix II

SUBSTANCE OF PROPOSED ACTION: To repeal the attachment to Rule 420-4-1-.14 since that rule is being repealed.

TIME, PLACE, AND MANNER OF PRESENTING VIEWS: A public hearing will be held at 9:00 a.m. July 29, 2014, at the Alabama Department of Public Health, RSA Tower, Suite 1540, 201 Monroe Street, Montgomery, AL 36104.

FINAL DATE FOR COMMENTS AND COMPLETION OF NOTICE: Written or oral comments will be received until the close of the record at 5:00 p.m. on <u>August 4, 2014</u>. All comments and requests for copies of the proposed amendments should be addressed to the contact person listed below.

CONTACT PERSON AT AGENCY: Sherri Davidson, Analysis and Reporting Branch Manager, Epidemiology Division of the Bureau of Communicable Disease, Department of Public Health, 201 Monroe Street, Suite 1460, Montgomery, Alabama 36104. Telephone number (334) 206-2050.

Patricia E. Ivie, Agency Secretary

Routine Prenatal Screening for Sexually Transmitted Diseases (STD)

APPENDIX II ATTACHMENT TO RULE 420-4-1-.14

Comments		 Document patient refusal Patients who declined testing should be offered test again during 3" trimester and/or in L&D 	 Confirmatory test indicated prior to notifying patient except when patient presents to L&D with no prenatal care; in this case, perform rapid test and follow up with confirmatory testing. 	,	
Labor and Delivery (L&D)	Indicated for all women	Offer if not done before	Indicated based on positive risk assessment*		
Third Trimester	Indicated based on positive risk assessment* (28 weeks' gestation)	Offer if not done before	Indicated based on positive risk assessment*	Indicated based on positive risk assessment*	Indicated based on positive risk assessment*
Initial Prenatal Visit	Indicated for all women	Indicated for all women not previously confirmed as HIV infected		 Age 24 and younger: Indicated for all women Age 25 and older: Indicated if unmarried OR based on positive risk assessment* 	 Age 24 and younger: Indicated for all women Age 25 and older: Indicated if unmarried OR based on positive risk assessment*
Test All tests must be FDA approved	Syphilis	<u></u>	-	Chlamydia	Gonorrhea

No Prenatal Care - Patient Presents at Delivery

Labor and Delivery	Indicated for all women	Indicated for all women not previously confirmed as HIV infected—use rapid test first and then a confirmatory test	Indicated if clinically feasible	Indicated if clinically feasible
Test	Syphilis	AIIV	Chlamydia	Gonorrhea

*Positive Risk Assessment - Presence of one or more risk factors including, but not limited to, a history of:

Multiple sex partners or an at-risk partner during the pregnancy Use of illicit drugs

STD during the pregnancy Exchanging sex for money or drugs

Author: Charles H. Woernle, M.D., M.P.H.
Statutory Authority: Code of Ala. 1975, \$\$22-2-2(6), 22-11A-1,
et. seq.
History: New Rule: Filed February 17, 2006; effective
March 24, 2006.